RU2664055C2 - Дигидронафтиридины и родственные соединения, подходящие в качестве ингибиторов киназ для лечения пролиферативных заболеваний - Google Patents

Дигидронафтиридины и родственные соединения, подходящие в качестве ингибиторов киназ для лечения пролиферативных заболеваний Download PDF

Info

Publication number
RU2664055C2
RU2664055C2 RU2014153920A RU2014153920A RU2664055C2 RU 2664055 C2 RU2664055 C2 RU 2664055C2 RU 2014153920 A RU2014153920 A RU 2014153920A RU 2014153920 A RU2014153920 A RU 2014153920A RU 2664055 C2 RU2664055 C2 RU 2664055C2
Authority
RU
Russia
Prior art keywords
naphthyridin
dihydro
oxo
ethyl
fluorophenyl
Prior art date
Application number
RU2014153920A
Other languages
English (en)
Russian (ru)
Other versions
RU2014153920A (ru
Inventor
Дэниел Л. Флинн
Майкл Д. Кауфман
Питер А. Петилло
Original Assignee
ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи filed Critical ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Publication of RU2014153920A publication Critical patent/RU2014153920A/ru
Application granted granted Critical
Publication of RU2664055C2 publication Critical patent/RU2664055C2/ru

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
RU2014153920A 2012-06-07 2012-06-07 Дигидронафтиридины и родственные соединения, подходящие в качестве ингибиторов киназ для лечения пролиферативных заболеваний RU2664055C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/041378 WO2013184119A1 (en) 2012-06-07 2012-06-07 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2018107578A Division RU2804468C2 (ru) 2018-03-01 Дигидронафтиридины и родственные соединения, подходящие в качестве ингибиторов киназ для лечения пролиферативных заболеваний

Publications (2)

Publication Number Publication Date
RU2014153920A RU2014153920A (ru) 2016-07-27
RU2664055C2 true RU2664055C2 (ru) 2018-08-14

Family

ID=49712374

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014153920A RU2664055C2 (ru) 2012-06-07 2012-06-07 Дигидронафтиридины и родственные соединения, подходящие в качестве ингибиторов киназ для лечения пролиферативных заболеваний

Country Status (28)

Country Link
EP (3) EP3722296A3 (https=)
JP (1) JP5883195B2 (https=)
KR (1) KR101652229B1 (https=)
CN (3) CN110433162A (https=)
AU (1) AU2012327210B2 (https=)
BR (1) BR112014030577B1 (https=)
CA (1) CA2875970C (https=)
CY (1) CY1123377T1 (https=)
DK (2) DK3366293T3 (https=)
ES (2) ES2663605T3 (https=)
FR (1) FR22C1013I2 (https=)
HR (1) HRP20200864T1 (https=)
HU (2) HUE049958T2 (https=)
IL (1) IL236110A (https=)
LT (2) LT3366293T (https=)
LU (1) LUC00253I2 (https=)
MX (2) MX372814B (https=)
NL (1) NL301169I2 (https=)
NO (1) NO2022010I1 (https=)
PH (2) PH12018502294B1 (https=)
PL (1) PL3366293T3 (https=)
PT (2) PT3366293T (https=)
RS (1) RS60406B1 (https=)
RU (1) RU2664055C2 (https=)
SG (1) SG11201408133TA (https=)
SI (1) SI3366293T1 (https=)
SM (1) SMT202000302T1 (https=)
WO (1) WO2013184119A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
MA38393B1 (fr) 2014-03-13 2018-11-30 Sanofi Sa Composés hétéroaryle et utilisations associées
SG11201805869XA (en) * 2016-01-11 2018-08-30 Merck Patent Gmbh Quinolin-2-one derivatives
CA3065365C (en) * 2017-05-30 2025-09-16 Deciphera Pharmaceuticals, Llc USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDINE-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ITS ANALOGUES FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN THE PLATELET-DERIVED GROWTH FACTOR ALPHA RECEPTOR
WO2019056990A1 (zh) * 2017-09-20 2019-03-28 浙江海正药业股份有限公司 1,2-二氢-1,6-萘啶类衍生物、其制备方法及其在医药上的用途
IL276398B2 (en) 2018-01-31 2026-03-01 Deciphera Pharmaceuticals Llc Combination therapy for mastocytosis
KR102708177B1 (ko) * 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
EP3938363A1 (en) * 2019-03-11 2022-01-19 Teva Pharmaceuticals International GmbH Solid state forms of ripretinib
US10927111B2 (en) 2019-05-03 2021-02-23 Kinnate Biopharma Inc. Inhibitors of RAF kinases
PT4013412T (pt) 2019-08-12 2026-03-18 Deciphera Pharmaceuticals Llc Ripretinib para o tratamento de tumores estromais gastrointestinais
LT4013412T (lt) 2019-08-12 2026-03-25 Deciphera Pharmaceuticals, Llc Ripretinibas, skirtas virškinamojo trakto stromos navikų gydymui
US20240075041A1 (en) * 2019-10-04 2024-03-07 Blueprint Medicines Corporation Treatment of eosinophilic disorders with avapritinib
BR112022007612A2 (pt) 2019-10-24 2022-09-20 Kinnate Biopharma Inc Inibidores de raf quinases
CN115243681B (zh) 2019-12-30 2024-08-16 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
HRP20231699T1 (hr) * 2019-12-30 2024-05-10 Deciphera Pharmaceuticals, Llc Formulacije inhibitora amorfne kinaze i postupci njihove primjene
KR102535840B1 (ko) 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도
US11407737B2 (en) 2020-09-18 2022-08-09 Kinnate Biopharma Inc. Inhibitors of RAF kinases
WO2022081469A1 (en) 2020-10-12 2022-04-21 Kinnate Biopharma Inc. Inhibitors of raf kinases
CN112625038A (zh) * 2020-12-31 2021-04-09 武汉九州钰民医药科技有限公司 制备瑞普替尼的方法
WO2022162690A1 (en) * 2021-01-28 2022-08-04 Dr. Reddy's Laboratories Limited Process for the preparation of ripretinib and solid state forms thereof
CN117561057A (zh) 2021-04-23 2024-02-13 金耐特生物制药公司 用raf抑制剂治疗癌症
EP4476218A1 (en) * 2021-12-24 2024-12-18 Assia Chemical Industries Ltd. Improved processes for the preparation of ripretinib
CN114213411B (zh) * 2022-01-24 2023-06-30 成都伊诺达博医药科技有限公司 一种瑞普替尼的合成方法
US11814384B2 (en) 2022-02-03 2023-11-14 Kinnate Biopharma Inc. Inhibtors of Raf kinases
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051757A1 (en) * 2006-10-20 2008-05-02 Irm Llc Compositions and methods for modulating c-kit and pdgfr receptors
US20080114006A1 (en) * 2006-09-14 2008-05-15 Deciphera Parmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US20110183997A1 (en) * 2008-02-22 2011-07-28 Irm Llc Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004279427B2 (en) * 2003-10-08 2008-07-03 Irm Llc Compounds and compositions as protein kinase inhibitors
DE102006030524A1 (de) * 2006-07-01 2008-01-03 Koch Transporttechnik Gmbh Verfahren und Vorrichtung zur Beseitigung von lockerem Material auf wellenförmigen Oberflächen gestampfter Kohle für die Verkokung
CN101516379A (zh) * 2006-09-14 2009-08-26 迪赛孚尔制药有限公司 可用于治疗增殖性疾病的激酶抑制剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080114006A1 (en) * 2006-09-14 2008-05-15 Deciphera Parmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
WO2008051757A1 (en) * 2006-10-20 2008-05-02 Irm Llc Compositions and methods for modulating c-kit and pdgfr receptors
US20080176846A1 (en) * 2006-10-20 2008-07-24 Irm Llc Compositions and methods for modulating c-kit and pdgfr receptors
US20110183997A1 (en) * 2008-02-22 2011-07-28 Irm Llc Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SIHTO ET AL., "KIT and Platelet-Derived Growth Factor Receptor Alpha Tyrosine Kinase Gene Mutations and KIT Amplifications in Human Solid Tumors.", JOURNAL OF CLINICAL ONCOLOGY., 2005, vol. 23, no. 1, PAGE 49-57. *

Also Published As

Publication number Publication date
HK1209345A1 (en) 2016-04-01
CA2875970C (en) 2017-07-04
DK3366293T3 (da) 2020-06-15
MX2014015024A (es) 2015-07-06
KR101652229B1 (ko) 2016-08-30
SI3366293T1 (sl) 2020-08-31
LTPA2022008I1 (https=) 2022-05-25
DK2858646T3 (en) 2018-03-19
EP2858646B1 (en) 2017-12-20
ES2663605T3 (es) 2018-04-16
PT2858646T (pt) 2018-03-27
EP3722296A2 (en) 2020-10-14
NO2022010I1 (no) 2022-04-07
AU2012327210A1 (en) 2014-01-09
PH12014502757A1 (en) 2015-03-02
CN110403938A (zh) 2019-11-05
EP2858646A1 (en) 2015-04-15
HUS2200017I1 (hu) 2022-06-28
HUE049958T2 (hu) 2020-11-30
SMT202000302T1 (it) 2020-07-08
RU2014153920A (ru) 2016-07-27
RS60406B1 (sr) 2020-07-31
JP5883195B2 (ja) 2016-03-09
CN110433162A (zh) 2019-11-12
AU2012327210B2 (en) 2016-07-28
LUC00253I2 (https=) 2025-03-04
CN104902895B (zh) 2019-03-29
CN104902895A (zh) 2015-09-09
FR22C1013I1 (fr) 2022-06-17
KR20150053894A (ko) 2015-05-19
NL301169I2 (nl) 2026-03-02
EP3366293B1 (en) 2020-03-11
SG11201408133TA (en) 2015-01-29
PH12018502294A1 (en) 2020-11-04
EP3366293A1 (en) 2018-08-29
PH12018502294B1 (en) 2024-02-28
ES2797252T3 (es) 2020-12-01
MX392372B (es) 2025-03-24
PH12014502757B1 (en) 2015-03-02
FR22C1013I2 (fr) 2022-12-30
CA2875970A1 (en) 2013-12-12
EP2858646A4 (en) 2015-09-02
LTC3366293I2 (https=) 2024-11-25
CY1123377T1 (el) 2021-12-31
IL236110A (en) 2016-11-30
PL3366293T3 (pl) 2020-09-21
IL236110A0 (en) 2015-01-29
MX372814B (es) 2020-07-03
MX2020005712A (es) 2022-05-17
BR112014030577A8 (pt) 2018-10-23
LT3366293T (lt) 2020-07-10
BR112014030577B1 (pt) 2022-02-08
PT3366293T (pt) 2020-06-18
JP2015520186A (ja) 2015-07-16
HRP20200864T1 (hr) 2020-08-21
EP3722296A3 (en) 2020-10-21
WO2013184119A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
RU2664055C2 (ru) Дигидронафтиридины и родственные соединения, подходящие в качестве ингибиторов киназ для лечения пролиферативных заболеваний
USRE48731E1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
DK3037424T3 (en) NEW QUINOLIN-SUBSTITUTED COMPOUND
JP2006503010A (ja) 数種の新規なイミダゾピリジンおよびその使用
WO2001002400A1 (en) Fused imidazole compounds and remedies for diabetes mellitus
TW200835485A (en) Novel aminopyrimidine derivatives as PLK1 inhibitors
CN113454081A (zh) 咪唑并吡啶基化合物及其用于治疗增生性疾病的用途
KR101905295B1 (ko) 나프티리딘디온 유도체
WO2022017494A1 (zh) 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用
JP2017516829A (ja) ピリドピリミジンジオン誘導体
CN118684666A (zh) Kif18a抑制剂及其用途
RU2804468C2 (ru) Дигидронафтиридины и родственные соединения, подходящие в качестве ингибиторов киназ для лечения пролиферативных заболеваний
WO2015014283A1 (zh) 蛋白酪氨酸激酶抑制剂及其应用
HK40039059A (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
HK1259893A1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
HK1259893B (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
HK1209345B (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
HUP0302440A2 (hu) Amino-kinolin származékok, eljárás előállításukra és ezeket hatóanyagként tartalmazó gyógyszerkészítmények